Loading
Aarti Drugs Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Alchemie Finserv Pvt. Ltd., was filed 01 Apr 2022.
Aarti Drugs Limited: what insiders have been doing
Aarti Drugs Limited belongs to the Health Care sector. Filings by its managers are published through SEBI (PIT + SAST). Over the twelve months to 26 October 2026, 1 filing were filed, from 1 insider.
All open-market trades in the period are sales: 1 sale, by 1 insider, with no purchase on record. The totals do not cover 1 filing with an undisclosed amount.
Compared with its exchange (1,891 companies, median 4 filings), a count of 1 filing is below the norm. Over the whole record (from 2021), the tally stands at 16 purchases and 12 sales.
A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEBI (PIT + SAST). They describe what insiders did and are not a recommendation.
Insider Decl.
68
Thresholds
n/a
Buy Volume
€2M
16 ops. · all time
Sell Volume
€3M
12 ops. · all time
Who traded when
BuySaleDilesh Roadlines Pvt Ltd & Others1 sale
Since the insiders bought
- -25.8%Entry ₹459.20 · Close at T+365 ₹340.90
- -25.8%Entry ₹459.20 · Close at T+365 ₹340.90
- -25.8%Entry ₹459.20 · Close at T+365 ₹340.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,906 of 26,320 companies
54.0
score / 100
Value54
Quality54
FCF yld2.3%
Earn yld5.7%
EV/EBITDA12.8x
ROE13%
Gross mgn20%
Net mgn7.7%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹374.90
Analyst consensus
1 analysts₹474.00Target ₹474.00(+26%)₹474.00
Income statement
Revenue₹25.2B
Gross profit₹5.1B20% margin
EBITDA₹3.1B12% margin
Net income₹1.9B7.1% margin
Valuation
PER (trailing)17.7x
PER (forward)13.4x
P/Book2.2x
Beta0.31
Balance sheet & cash
Market cap₹34.2B
Total debt₹5.8B
Free Cash Flow₹802.2M
Debt / Equity37%
Profitability & ownership
ROE13.4%
ROA5.7%
% insiders59.6%
% institutions11.0%
Last declaration on 14 July 2026
Declarations68 total
2,265,795 shares-MarketSEBI:62cce9b2d8b2bf8dd3ce298dd70a96a8cfe77c2b
164,500 shares@ ₹438.130443.6% of flowEquity SharesSEBI:3a9fe497324dac3c2285044272b150405bdf912a
11,000 shares@ ₹440.780213.3% of flowEquity SharesSEBI:4c7b82e7d5ad6bb2bba5c445d591797c0c9b31d6
Canonical exit: 29 Jun 2022 (T+90)
50,000 shares@ ₹440.73322.0% of flowEquity SharesSEBI:772990de212fbe437710799e3934274cb217caf4
Canonical exit: 29 Jun 2022 (T+90)
53,500 shares@ ₹437.210834.9% of flowEquity SharesSEBI:7ebe6f289a05c28eb6e8501faf6fa394e23439f6
Canonical exit: 29 Jun 2022 (T+90)
14,000 shares@ ₹440.780316.9% of flowEquity SharesSEBI:705cb443842637d2a2db1fe008dae568c5d04138
Canonical exit: 29 Jun 2022 (T+90)
25,000 shares@ ₹440.77939.3% of flowEquity SharesSEBI:747147572648e5e25866cf3fc68dd6efdb9fa581
Canonical exit: 29 Jun 2022 (T+90)
120,000 shares@ ₹440.536264.7% of flowEquity SharesSEBI:4cb306523b3cff167265c8eaccd8fb3d6fd2bf08
Canonical exit: 26 Jun 2022 (T+90)
70,000 shares@ ₹438.945746.0% of flowEquity SharesSEBI:4dd9d6ec3cd7435e359970ce740b30cd8c75106c
Canonical exit: 26 Jun 2022 (T+90)
180,615 shares@ ₹439.28248.2% of flowEquity SharesSEBI:9e317954615d4f72aad39c2c6b33b859a0370625
609 shares@ ₹459.35336.8% of flowEquity SharesSEBI:291c302e44702c60108378a3b14559eb6e4281b3
Canonical exit: 31 May 2022 (T+90)
500 shares@ ₹520.98223.7% of flowEquity SharesSEBI:628de7709512da35f476ccd9d68b904cdfbb417b
Canonical exit: 20 Mar 2022 (T+90)
20 shares@ ₹520.601.0% of flowEquity SharesSEBI:3206cff2e73608a9d0375a3fed090c3190f2a56c
Canonical exit: 22 Feb 2022 (T+90)
500 shares@ ₹459.70821.0% of flowEquity SharesSEBI:eed19423223a3c4a224e31e9f0dab6e1b1a38dc8
Canonical exit: 29 May 2022 (T+90)
500 shares@ ₹517.70623.6% of flowEquity SharesSEBI:a1d92dbd4a5f7f0bd032964a1312b71fbddf2ef0
Canonical exit: 1 Mar 2022 (T+90)
8,600 shares@ ₹503.07954.2% of flowEquity SharesSEBI:b00f8633b13ba29b8481f45487a317d3cfbf87e8
Canonical exit: 16 May 2022 (T+90)
10,000 shares@ ₹524.06265.2% of flowEquity SharesSEBI:3e15f0aadcb9df236aa025e38d215cf3f70ecc06
71,258 shares@ ₹524.543837.5% of flowEquity SharesSEBI:ff9bd60328c1d7a36c7c8315373282d9ca146315
13,120 shares@ ₹526.43486.9% of flowEquity SharesSEBI:d15ece23fe7275bb06d4145c4ad33b62f4bde008
8,705 shares@ ₹522.20644.5% of flowEquity SharesSEBI:be1f323b539b4719e2257bdf50cb32b5ca21cc5e
45,000 shares@ ₹523.128423.5% of flowEquity SharesSEBI:f86e303f1bce743f0148e37e7c58c9aecb569798
1,917 shares@ ₹522.91181.0% of flowEquity SharesSEBI:70713a810f0014cfb0ba8d519edd770551804385
200 shares@ ₹517.5750.1% of flowEquity SharesSEBI:3c10af7cc70cfd376b05420835f7e57129416b71
Canonical exit: 21 Mar 2022 (T+90)
10,741 shares@ ₹512.44265.4% of flowEquity SharesSEBI:280e403ce2e39363ac5a4224f3f94a251f92548c
Canonical exit: 1 Mar 2022 (T+90)
19,200 shares@ ₹519.54989.9% of flowEquity SharesSEBI:d97b94d555595295656c643f997bec9d945c325f
Canonical exit: 28 Feb 2022 (T+90)
25 of 68 declarations
About Aarti Drugs Limited
Aarti Drugs Limited is an Indian company engaged in the manufacturing of pharmaceutical products. It is listed on the Bombay Stock Exchange.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
